Recent research has suggested that the growth of central nervous system (CNS) axons during development is mediated through the PI3K/Akt/mammalian target of rapamycin (mTOR) intracellular signalling axis and that suppression of activity in this pathway occurs during maturity as levels of the phosphatase and tensin homologue (PTEN) rise and inhibit PI3K activation of mTOR, accounting for the failure of axon regeneration in the injured adult CNS. This hypothesis is supported by findings confirming that suppression of PTEN in experimental adult animals promotes impressive axon regeneration in the injured visual and corticospinal motor systems. This review focuses on these recent developments, discussing the therapeutic potential of a mTOR-based treatment aimed at promoting functional recovery in CNS trauma patients, recognising that to fulfil this ambition, the new therapy should aim to promote not only axon regeneration but also remyelination of regenerated axons, neuronal survival and re-innervation of denervated targets through accurate axonal guidance and synaptogenesis, all with minimal adverse effects. The translational challenges presented by the implementation of this new axogenic therapy are also discussed.
Introduction
Recent research aimed at promoting axon regeneration in the injured central nervous system (CNS) has achieved impressive regrowth of long axonal tracts by activation of the phosphatidylinositol/protein kinase B/mammalian target of rapamycin intracellular signalling pathway (PI3K/Akt/mTOR; mTOR is used throughout as an inclusive term for mTORC1 and mTORC2 -abbreviations of all signalling molecules are given in Fig. 1 ) (reviewed by Liu et al., 2011; Kanno et al., 2012; Aruni et al., 2012; Maiese et al., 2013; Maiese, 2014; Lu et al., 2014a) . These and others studies attribute the poor prognosis for functional restitution to suppression, at around birth, of developmental mTORmediated neuroprotection and axogenic protein synthesis (Park et al., 2008 (Park et al., , 2010 He, 2010; Pernet and Schwab, 2014) . This proposition predicts that treatments which re-establish the sensitivity of the PI3K/Akt pathway to growth factor activation in maturity augur well for the restoration of function in CNS trauma patients. 
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